1.
Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury
by Baeck, Christer
Gut, 2012-03, Vol.61 (3), p.416-426
2.
Acute liver failure
by Bernal, William, Dr
The Lancet (British edition), 2010, Vol.376 (9736), p.190-201
3.
Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer
by Schneider, Carlo
Gut, 2012-12, Vol.61 (12), p.1733-1743
4.
Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study
by Tateishi, Ryosuke
Journal of gastroenterology, 2014-06-15, Vol.50 (3), p.350-360
5.
6.
Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer
by Malehmir, Mohsen
Nature medicine, 2019-04, Vol.25 (4), p.641-655
7.
Hepatocellular carcinoma
by Forner, Alejandro, MD
The Lancet (British edition), 2012, Vol.379 (9822), p.1245-1255
8.
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
by McPherson, Stuart
Gut, 2010-09, Vol.59 (9), p.1265-1269
9.
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
by Marengo, Andrea
Annual review of medicine, 2016-01-14, Vol.67 (1), p.103-117
10.
Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study
by Katoonizadeh, Aezam
Gut, 2010-11, Vol.59 (11), p.1561-1569
11.
Increasing burden of liver disease in patients with HIV infection
by Joshi, Deepak, MRCP
The Lancet (British edition), 2011, Vol.377 (9772), p.1198-1209
12.
Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years
by Roulot, Dominique
Gut, 2011-07, Vol.60 (7), p.977-984
13.
NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease
by Syn, Wing-Kin
Gut, 2012-09, Vol.61 (9), p.1323-1329
14.
Improvement of liver function parameters in advanced HCV‐associated liver cirrhosis by IFN‐free antiviral therapies
by Deterding, K.
Alimentary pharmacology & therapeutics, 2015-10, Vol.42 (7), p.889-901
15.
Safety profile of autologous macrophage therapy for liver cirrhosis
by Moroni, Francesca
Nature medicine, 2019-10, Vol.25 (10), p.1560-1565
16.
The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection
by Schindl, M J
Gut, 2005-02, Vol.54 (2), p.289-296
17.
Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwid...
by Tokushige, Katsutoshi
Journal of gastroenterology, 2011-07-13, Vol.46 (10), p.1230-1237
18.
Pediatric non-alcoholic fatty liver disease: an increasing public health issue
by Berardis, S
European journal of pediatrics, 2013-09-26, Vol.173 (2), p.131-139
19.
G protein-coupled estrogen receptor deficiency accelerates liver tumorigenesis by enhancing inflammation and fibrosis
by Wei, Tao
Cancer letters, 2016, Vol.382 (2), p.195-202
20.
